- Article metrics
- Last updated: Thu, 25 Apr 2024 12:18:30 Z
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
Access & Citations
-
- 2002
- Article Accesses
-
- 0
- Web of Science
-
- 25
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.